SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that ...

He holds a B.S. from Yale College and an M.D. from Harvard Medical School. His academic accolades include a chief residency and a Howard Hughes postdoctoral fellowship at UCSF. Rigel’s president ...

March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical ...

Q4 2024 Earnings Call Transcript March 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.8, expectations were $0.3. Operator: Greetings, and welcome to Rigel ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.

Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET. Company Participants. Ray Furey - Executive Vice President, General Counsel & ...